Michael Cookson, MD,MHA

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Prokarium
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Nonagen Bioscience Corp.
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    MJH LifeSciences
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Health Publishing (Oncology)
    Ineligible company: 
    BioPharm Communications
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Clinical Education Alliance, LLC
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pacifice Edge Diagnostics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    TesoRx Pharma LLC
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer Healthcare Pharmaceuticals
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myovant Sciences
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022

Pages

Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion: A Virtual Course (2022)